<code id='18031F7D75'></code><style id='18031F7D75'></style>
    • <acronym id='18031F7D75'></acronym>
      <center id='18031F7D75'><center id='18031F7D75'><tfoot id='18031F7D75'></tfoot></center><abbr id='18031F7D75'><dir id='18031F7D75'><tfoot id='18031F7D75'></tfoot><noframes id='18031F7D75'>

    • <optgroup id='18031F7D75'><strike id='18031F7D75'><sup id='18031F7D75'></sup></strike><code id='18031F7D75'></code></optgroup>
        1. <b id='18031F7D75'><label id='18031F7D75'><select id='18031F7D75'><dt id='18031F7D75'><span id='18031F7D75'></span></dt></select></label></b><u id='18031F7D75'></u>
          <i id='18031F7D75'><strike id='18031F7D75'><tt id='18031F7D75'><pre id='18031F7D75'></pre></tt></strike></i>

          Home / Wikipedia / entertainment

          entertainment


          entertainment

          author:explore    Page View:3
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In